Syneos Health Inc (SYNH) Return on Equity ROE from the second quarter 2023 to second quarter 2022 and annually, average high and low, overall ranking from Jun 30 2023 to Jun 30 2022 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Syneos Health Inc   (NASDAQ: SYNH)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare

Syneos Health Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Syneos Health Inc in the second quarter 2023?
Syneos Health Inc achieved a return on average equity (ROE) of 2.06 % in its second quarter 2023, which is below Syneos Health Inc 's average return on equity, which stands at 9.62%.

ROE fell compared to the first quarter 2023, despite the net income growth of % from the first quarter 2023.

Within the Medical Laboratories industry 10 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2023 from 1951 to 2231.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter		 (Jun 30 2022)
II. Quarter
Y / Y Equity Change 4.95 % 4.63 % 2.42 % 1.02 % -
Y / Y Net Income Change -98.98 % - -26.9 % 11.25 % 85.52 %
Net Income (TTM) in Millions 71 148 266 287 278
Return On Equity (TTM) 2.06 % 4.35 % 7.91 % 8.57 % 8.32 %
SYNH's Total Ranking # 2231 # 1951 # 1850 # 1562 # 1804
Equity (TTM) in Millions 3,494 3,454 3,495 3,354 3,329
Seq. Equity Change 1.14 % -1.16 % 4.2 % 0.75 % 0.83 %
Seq. Net Income Change - - -36.21 % 11.97 % 68.36 %

Back to SYNH Management Effectiveness >> SYNH's 5 Years Annual ROE >> Compare SYNH ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 11
Sector # 170
Overall # 2231

Return On Equity Statistics
High Average Low
43.23 %
9.62 %
-16.51 %
(Jun 30 2016)   (Jun 30 2015)





SYNH Annual Return On Equity (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018
Total Equity in Millions 3,495 3,413 3,242 3,030 2,856
Y / Y Equity Change 2.42 % 5.26 % 7.01 % 6.07 % -5.51 %
Net Income in Millions 266 235 193 131 24
Y / Y Net Income Change 13.48 % 21.81 % 46.88 % 440.51 % -
Return On Equity 7.63 % 6.88 % 5.95 % 4.33 % 0.85 %

Back to SYNH Management Effectiveness >> SYNH's 5 Years Annual ROE >> Compare SYNH ROE to its Competitors




Annual Roe Comment
In 2022 ROE improved to 7.63 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Medical Laboratories Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
SYNH's' Return on Equity at Yahoo Finance
SYNH's Roe Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for SYNH's Competitors
Subscribers only: Roe for Syneos Health Inc 's Suppliers
Subscribers only: Return On Equity for SYNH's Customers




Companies with similar Return On Equity at Jun 30 2023, within Healthcare Sector ROE
Privia Health Group Inc   5.64 %
Macrogenics Inc   5.46 %
Envista Holdings Corporation  5.18 %
Sensus Healthcare Inc   5.09 %
Boston Scientific Corporation  5.08 %
Integer Holdings Corporation  5.05 %
Eagle Pharmaceuticals inc   4.98 %
Supernus Pharmaceuticals inc   4.86 %
Royalty Pharma Plc  4.76 %
Third Harmonic Bio Inc   4.65 %
Lakeland Industries Inc   4.50 %
Docgo Inc   4.39 %
Pacific Health Care Organization Inc  4.39 %
Nature s Sunshine Products inc   4.25 %
Zimmer Biomet Holdings Inc   4.15 %
Ligand Pharmaceuticals Incorporated  3.99 %
Organogenesis Holdings Inc   3.80 %
The Cooper Companies Inc   3.76 %
National Healthcare Corp  3.37 %
Nuvasive Inc  3.28 %
Surgery Partners Inc   3.20 %
National Vision Holdings Inc   2.89 %
Penumbra Inc  2.87 %
Vanda Pharmaceuticals Inc   2.81 %
Inmed Pharmaceuticals Inc  2.69 %
Adapthealth Corp   2.18 %
Biomarin Pharmaceutical Inc  2.15 %
Radnet Inc   2.12 %
American Shared Hospital Services  2.12 %
Syneos Health Inc   2.06 %

Date modified: 2026-09-08T15:11:01+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.